We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Letrozole (Femara) — non-steroidal aromatase inhibitor
A potent non-steroidal aromatase inhibitor (Femara) that blocks estrogen synthesis. Approved for hormone-receptor-positive breast cancer, it is also the evidence-backed first-line drug for ovulation induction in PCOS — where a landmark NEJM RCT showed it BEAT clomiphene on live births. Used off-label in men to raise testosterone and lower estradiol, but that estrogen suppression harms bone and lipids, and in growing boys it carries a vertebral-deformity signal. A prescription drug, not a supplement, and NOT a longevity drug.
Prescription medication — not a dietary supplement
Letrozole is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Letrozole doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2003–2026 with a typical study size of 42 participants.
Based on 99 studies · 21 meta-analyses · 70 RCTs · 7,368 total participants
Confidence
High confidenceBy outcome
Letrozole has guideline-grade evidence for female ovulation induction — a landmark NEJM RCT and high-certainty Cochrane reviews show it beats clomiphene on live births in PCOS — plus an approved breast-cancer role. But the off-label male use (raising testosterone by suppressing estradiol) showed NO somatic/psychological benefit in a placebo-controlled RCT and carries real bone and lipid costs, and in growing boys it raised vertebral-deformity prevalence (45% vs 0% on placebo). Strong where it is strong, genuinely risky off-label, and NOT a longevity agent — so it stays emerging overall.
72 randomised trials
82% were about Letrozole in an audit of 50 of them
Every randomised or controlled trial of Letrozole indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Sep 2026
272 trials ongoing or recruiting · 388 completed on ClinicalTrials.gov
135 of the completed trials have posted results
Registered trials show research momentum for Letrozole, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Letrozole is a third-generation non-steroidal aromatase inhibitor (AI) that reversibly blocks the aromatase (CYP19A1) enzyme, the step that converts androgens to estrogens. By suppressing estradiol it serves two very different clinical purposes.
Its approved use is in postmenopausal hormone-receptor-positive breast cancer, where lowering circulating estrogen starves estrogen-dependent tumors.
Its strongest fertility evidence is in ovulation induction: in women with polycystic ovary syndrome (PCOS), lowering estrogen transiently releases the hypothalamic-pituitary axis from estrogen feedback, raising FSH and recruiting a dominant follicle.
The landmark NICHD/Legro NEJM trial (750 women) randomized letrozole versus clomiphene and found letrozole produced more cumulative live births (27.5% vs 19.1%) and higher ovulation rates, with no significant difference in pregnancy loss or twin pregnancy, and four major congenital anomalies with letrozole vs one with clomiphene (P=0.65).
A 2022 Cochrane review pooled 41 RCTs (6,522 women) and reached high-certainty conclusions that letrozole improves live-birth and pregnancy rates over clomiphene in anovulatory PCOS, with similar OHSS rates — which is why guidelines now place letrozole first-line for PCOS ovulation induction even though that indication is off-label in many regions.
In men, the same mechanism (lower estradiol, less negative feedback) raises LH, FSH, and testosterone; a 6-month RCT in 42 obese hypogonadal men found letrozole raised testosterone about 2.5-fold and halved estradiol.
The honest male-use caveat is large: a double-blind RCT in obese men found that despite a marked testosterone rise, low-dose letrozole produced NO somatic or psychological benefit.
Estrogen is essential for male bone and lipid health, so chronic aromatase inhibition risks bone loss and adverse lipids, although that 6-month trial found no significant change in lipid or bone metabolism and longer use was not tested.
In growing boys, letrozole delays bone-age advancement and increases predicted adult height in short stature / constitutional delay — but the strongest counter-evidence is a bone study showing mild vertebral-body deformities in 5 of 11 (45%) letrozole-treated boys versus none on placebo, a mandatory honesty limit when AIs are used during growth.
The score reflects genuinely strong, guideline-grade evidence for female ovulation induction (better than clomiphene) and an established oncology role, set against off-label male use whose benefit is unproven and whose estrogen suppression carries real bone/lipid costs.
Letrozole is a prescription drug, not a supplement, and there is no longevity rationale — it is not and should not be tagged as a longevity drug.
Letrozole reversibly blocks the aromatase enzyme that converts androgens (testosterone, androstenedione) into estrogens, lowering circulating estradiol throughout the body.
Lower estradiol means less negative feedback on the hypothalamus and pituitary, which raises FSH and LH. In women this recruits a dominant follicle for ovulation; in men it drives the testes to make more testosterone.
In hormone-receptor-positive breast cancer, low estrogen starves estrogen-dependent tumors. In growing children, estrogen normally fuses growth plates, so suppressing it delays bone-age advancement and can increase predicted adult height.
How Letrozole works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
This is the strongest-evidence use — first-line ovulation induction, beating clomiphene on live births. Use under a fertility clinician; stop once pregnant.
It does raise testosterone and lower estradiol, but a placebo-controlled RCT showed no symptomatic benefit, and estrogen suppression harms bone and lipids. Not a validated TRT alternative; monitor estradiol, bone density, and lipids if used at all.
Investigational; can increase predicted height but carries a vertebral-deformity signal. Only under pediatric endocrinology with spine monitoring.
Teratogenic — must not be taken during an established pregnancy. Ovulation-induction courses are given before conception and stopped once pregnancy is confirmed.
Overlapping or opposing effects on the estrogen axis; tamoxifen can reduce letrozole plasma levels when co-administered.
Estrogen supplementation works directly against letrozole's mechanism and would blunt its effect.
Often stacked off-label to control estradiol, but combining androgens with aromatase inhibition can drive estradiol too low and worsen bone/lipid effects; not a validated protocol.
Tip: A direct consequence of low estrogen; usually tolerable and reversible on stopping.
Tip: Reported more with letrozole than clomiphene in the ovulation-induction trial; usually transient.
Tip: Estrogen-deprivation joint symptoms, well known from long-term breast-cancer use.
Tip: Estrogen is needed for bone and lipid health; monitor bone density and lipids with prolonged or off-label male use.
Tip: Mild vertebral deformities occurred in 45% of letrozole-treated boys vs 0% on placebo; if used during growth, follow vertebral morphology.
Letrozole has an evidence score of 5/10 — moderate evidence based on 99 indexed studies, including 1 meta-analysis. A potent non-steroidal aromatase inhibitor (Femara) that blocks estrogen synthesis. Approved for hormone-receptor-positive breast cancer, it is also the evidence-backed first-line drug for ovulation induction in PCOS — where a landmark NEJM RCT showed it BEAT clomiphene on live births. Used off-label in men to raise testosterone and lower estradiol, but that estrogen suppression harms bone and lipids, and in growing boys it carries a vertebral-deformity signal. A prescription drug, not a supplement, and NOT a longevity drug. Representative study: PMID 36165742.
Dosing for Letrozole: Indication-specific and clinician-directed. Ovulation induction: 2.5-7.5 mg once daily for 5 days early in the cycle (typically days 3-7). Breast cancer: 2.5 mg once daily continuously. Off-label male use mirrors 2.5 mg once to a few times weekly (NOT daily) titrated to testosterone/estradiol — a prescription drug, not an approved supplement regimen. Individual needs vary, so check the right dose for you with a healthcare provider.
Timing is flexible for Letrozole — consistent daily use matters more than the time of day. Taken orally with or without food.
Letrozole should be used with caution — talk to a healthcare provider before taking it. Reported side effects include skeletal findings in growing boys, bone loss / adverse lipids with chronic use, hot flashes. How often they occur is not established for all of them. Use caution if any of these apply to you: Pregnancy (teratogenic risk) — used to induce ovulation, but stopped once pregnancy occurs; Premenopausal women for breast-cancer indication without ovarian suppression; Hypersensitivity to letrozole.
CoQ10
Likely helpsA lipid-soluble antioxidant central to mitochondrial energy production, with the strongest trial support for fertility/IVF outcomes and heart failure.
DHEA
Probably helpsAdrenal hormone precursor that declines with age. In postmenopausal women with normal adrenal function, trials found no effect on sexual symptoms or metabolic markers.
Clomiphene (Clomid)
Too few graded studiesA racemic selective estrogen receptor modulator (SERM) that has been FDA-approved for decades for female ovulation induction, and is used off-label in men with secondary (low-LH) hypogonadism to raise endogenous testosterone. By blocking estrogen feedback at the hypothalamus it increases LH and FSH, driving the testes to make more testosterone — unlike testosterone gels/injections, which suppress both. Honest appraisal: clomiphene is the RACEMIC mixture of enclomiphene (trans, the active estrogen-antagonist isomer) and zuclomiphene (cis, a long-lived weakly estrogenic isomer that accumulates) — the zuclomiphene downside is the entire reason the single-isomer enclomiphene was developed. Male use is off-label, the evidence is mostly observational and surrogate-based (testosterone/LH/FSH), and there are NO long-term hard-outcome trials. It is NOT a longevity drug.
Progesterone
Too few graded studiesThe endogenous steroid hormone, sold as a prescription bioidentical (micronized) drug (Prometrium / Utrogestan). It is the ENDOMETRIAL-PROTECTION half of menopausal hormone therapy (it opposes estrogen, and in the PEPI trial prevented estrogen-driven endometrial hyperplasia), and is used for luteal support in IVF and to treat secondary amenorrhea. Oral micronized progesterone is also widely used OFF-LABEL for menopausal SLEEP and hot flashes, because a metabolite (allopregnanolone) is GABA-active and sedating. Randomized trials support these specific indications; in early-pregnancy bleeding the large PRISM trial found no significant increase in live births. It is NOT a general healthy-population enhancer, and the breast-cancer signal from older synthetic progestins (WHI) should not be assumed for micronized progesterone, where data suggest it is more breast- and metabolically neutral but longer-term evidence is limited. Prescription-only and NOT a dietary supplement; OTC 'progesterone creams' absorb erratically and are not equivalent.
Explore: Best supplements for Women's Health
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 99 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research